Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...

The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics ...

VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, ...

Since its inception, Akeso Biopharma has remained steadfast in its commitment to original innovation in drug development. Through a differentiated strategy and forward-thinking approach, the company ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

the company has forged 10 global collaborations, advancing seven clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across ...

EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The ?54 million Series A funding round is aimed at accelerating the clinical development of a ...